Neurochemical Aspects in Dual Pathology
International Journal of Dual Diagnosis
Volume 1, Issue 1, March 2016, Pages: 1-8
Received: Mar. 3, 2016; Accepted: Mar. 11, 2016; Published: Apr. 14, 2016
Views 3353      Downloads 205
Authors
Montes Reula L., Mental Central Health Net, Department of Psychiatry, Pamplona, Spain
Barrado Los Arcos L., Mental Central Health Net, Department of Psychiatry, Pamplona, Spain
Arbeo Ruiz O., Centro de Día Zuría Department of Psychiatry, Pamplona, Spain
Article Tools
Follow on us
Abstract
There are a lot of brain circuits, neurotransmitters and subtances involved in the ethiopathogenesis of Dual Disorders. In the last tem years many researchs have tried to explain woich of the Brian mechanism could paly a role in this disorder. In this revision, we make a review of the most robust and conluyents papers about the neuchemical mechanism with the objective to understand the disease and help to discrimante the best psychopharmacological treatment.
Keywords
Brain System, Neurotransmitters, Ethiopathogenesis
To cite this article
Montes Reula L., Barrado Los Arcos L., Arbeo Ruiz O., Neurochemical Aspects in Dual Pathology, International Journal of Dual Diagnosis. Vol. 1, No. 1, 2016, pp. 1-8. doi: 10.11648/j.ijdd.20160101.11
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
Bush G, Vogt BA, Holmes J, Dale AM, Greve D, Jenike MA, Rosen BR (2002) Dorsal anterior cingulated cortex: a role in reward-based decision making. Proc Natl Acad Sci USA; 99: 523-528.
[2]
Koob GF, Le Moal M (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology; 24: 97-129.
[3]
McFarland K, Kalivas PW (2001) The circuitry mediating cocaine-induced reinstatement of drug-seeking behaviour. J. Neurosci; 21: 8655-8663.
[4]
See RE, Kruzich PJ, Grimm JW (2001) Dopamine, but not glutamate, receptor blockade in the basolateral amygdale attenuates conditioned reward in a rat model of relapse to cocaine-seeking behaviour. Psychopharmacology (Berl); 154: 301-310.
[5]
Robinson TE, Berrigde KC (2003) Addiction. Annu Rev Psychol; 54: 25-53.
[6]
Volkow ND, Fowler JS, Wang GJ, Swanson JM (2004) Dopamine in drug abuse and addiction: results from Imaging Studies and treatment implications. Mol Psychiatry; 9: 557-569.
[7]
Volkov ND, Logan J, Fowler JS, Wang GJ, Gur RC, Wong C, et al (2000) Association between agerelated decline in the brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry; 157:75-80.
[8]
Alamo C., Lopez-Mnuñoz F., Cuenca E (2000) Abordaje farmacológico de las recaídas en adicciones. Adicciones; 12 (4): 527-539.
[9]
Vocci FJ, Acri J, Elkashef A (2005) Medication development for addictive disorders: The state of the science. Am J Psychiatry; 162(8): 1432-1440.
[10]
Epstein DH, Preston KL, Jasinski DR (2006) Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol. Biol Psychol; 73: 90-99.
[11]
Mach RH, Nader MA, Green KL, Luedtke RR (1999) The effects of benzamide analogues on cocaine self-administration in rhesus monkeys. Pychopharmacology; 147(2): 143-152.
[12]
Regier DA, Farmer ME, Rae DS, et al (1990) Comorbidity of mental disorders with alcohol and other drug abuse: results from The Epidemiologic Catchment Area (ECA) study. JAMA; 264: 2511-2518.
[13]
Elzo J, et al (2000) Las culturas de las drogas en los jóvenes. Ritos y fiestas. Vitoria. Publicación del Gobierno Vasco, 2000.
[14]
Portella E, Ridao M, Carrillo E, Ribas E (1998) El alcohol y su abuso: Impacto socioeconómico. Madrid: Editorial Médica Panamericana.
[15]
George AK, Mcgeary J, Robert MS (2004) Farmacoterapia, farmacogenómicas y el futuro del tratamiento de la dependencia del alcohol. Revista de Toxicomanías; 41: 3-8.
[16]
Johnson BA, Ait-Daoud N (2000) Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology; 149: 327-344.
[17]
San L, Arránz B (2003) Tratamiento de la dependencia de alcohol. Técnicas farmacológicamente apoyadas. En: Manual SET de alcoholismo. Editorial Panamericana; 18: 437-450.
[18]
Marta T (2001) El papel de la farmacoterapia: nuevas perspectivas en el tratamiento de las drogodependencias y alcoholismo. Cuadernos de Psiquiatría Comunitaria;1:57-60.
[19]
Myrick H, Anton RF (1998) Treatment of alcohol withdrawal. Alcohol Health Res World; 22(1):38-43.
[20]
Koob GF, Nestler EJ (1997): The neurobiology of drug addiction. J Neuropsychiatry Clin Neurosci.; 9(3):482-97.
[21]
Volkow ND et al (2001) Low level of brain dopamine D2 receptors in methamphetamine abusers: association with metabolism in the orbitofrontal cortex. Ame J Psychiatry, 158:2015–2021.
[22]
Alele PE, Devaud LL: (2005) Differential adaptations in GABAergic and glutamatergic systems during ethanol withdrawal in male and female rats. Alcohol Clin Exp Res.; 29(6):1027-34.
[23]
Diamond I, Gordon AS (1997) Cellular and molecular neuroscience of alcoholismo. Physiol Rev; 77:1:20
[24]
Rogawski MA (2005) Update on the neurobiology of alcohol withdrawal seizures. Epilepsy; 5(6):225-30.
[25]
Santo–Domingo J, Jiménez–Arriero M.A (2007) Consenso de la Sociedad Española de Psiquiatría sobre Diagnóstico y Tratamiento del Alcoholismo y otras Adicciones.
[26]
Euromedice ediciones médicas 2003.
[27]
Allan C, Smith I, Mellin M (200) Detoxification from alcohol: a comparison of home detoxification and hospital-based day patient care. Alcohol Alcohol.; 35(1):66-9.
[28]
Shaw GK, Waller S, Latham CJ, Dunn G, Thomson AD (1998) The detoxification experience of alcoholic in-patients and predictors of outcome. Alcohol Alcohol.; 33(3):291-303.
[29]
Thomson AD, Marshall EJ (2006) The treatment of patients at risk of developing Wernicke's encephalopathy in the community. Alcohol Alcohol.;41(2):159-67.
[30]
Rubio G, Santo-Domingo J (2000) Guía Práctica de Intervención en el Alcoholismo. Madrid. Agencia Antidroga, Comunidad de Madrid.
[31]
Seifert J, Peters E, Jahn K, Metzner C, Ohlmeier M, Wildt B, Emrich HM, Schneider U (2004) Treatment of alcohol withdrawal: chlormethiazole vs. carbamazepine and the effect on memory performance-a pilot study. Addict Biol.; 9(1):43-51.
[32]
John E. McGeary, PhD (2004) Genetic Influences on Addiction: Empirical Evidence, Functional Mechanisms, and Clinical Implications. Providence VMAC Center for Alcohol and Addiction Studies, Brown University.
[33]
O’Malley S. S, Jaffe A. J, Chang G, Rode, S, Schttenfeld R, Meyer R.E, Rounsaville B (1996) Six-month follow-up of Naltrexone and psychotherapy for alcohol dependence. Arch. Gen Psychiatry; 53:217-224.
[34]
San L, Arranz B (1999) Toxicomanía y primer episodio psicótico. En Pichot J, Ezcurra A, González-Pinto y M- Gutiérrez-Fraile.
[35]
Addolorato G, Caputo F, Capristo E, Domenicali M, Bernardi M, Janiri L. et al (2002) Baclofen efficacy inreducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol and Alcoholism; 37(5):504-8.
[36]
Chick J, Lehert P, Landon F (2003) Does acamprosate improve reduction of drinking as well as aiding abstinence?. Jornal of Psychofarmacology,; 17(4):397-402.
[37]
Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al (2006) COMBINE Study Research Group. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA; 295:2003-17.
[38]
Cornelius JR, Salloum IM, Ehler JG, Jarrett PJ, Cornelius MD, Perel JM, Thase ME, Black A (1997) Fluoxetine in depressed alcoholics. Adouble-blind, placebo-controlled trial. Am J Psychiatry; 54: 700-705.
[39]
O´Brien CP (2007) Fármacos que disminuyen el deseo de droga para la prevención de la recaída. Clinical Psichiatry Self-Assessment Program: Guía clínica para el tratamiento de los pacientes con trastornos por abuso de sustancias. Publicado en USA por la American Psychiatric Plubishing Inc., pp; 108-109.
[40]
Montes M, Baño D, Jimenez JM, Otero F, Ruiz de Apodaka J, Sánchez R (2004) Programas de mantenimiento con agonistas opiáceos. En: Fernández-Miranda JJ, Gutierrez E, Marina PA: Actuaciones clínicas en trastornos adictivos. Madrid. Aula Médica: pp 303-336.
[41]
Crespo J.A, Martin S, Ambrosio E (2001) Neuroadaptaciones en los sistemas Glutamatérgico y Dopaminérgico durante la abstinencia de la cocaína. Adicciones,;13 (1): 7-16.
[42]
Caballero L (2005) Adicción a cocaína: neurobiología, clínica, diagnóstico y tratamiento. Delegación del Gobierno para el Plan Nacional sobre Drogas, pp 31-33 and 142-152
[43]
Marset M (2007) Abordaje terapéutico de los trastornos relacionados con la dependencia de cocaína en: Camarasa J, Jimenez-Arriero MA, Rubio G: Adicciones, aspectos clínicos y terapéuticos. Edika Med,; 39
[44]
Kantak KM: (2003) Vaccines against drugs of abuse: a viable treatment option?. Drugs; 63: 341-52.
[45]
Carrera MRA, Ashley JA, Parsons LH, Wirsching P, Koob GF, Janda KD (1995) Suppression of psychoactive effects of cocaine by active inmunization. Nature.; 378:727-30
[46]
Lichtman AH, Martin BR (2005) Cannabinoid tolerance and depende. Handbook of experimental pharmacology; 168: 691-717.
[47]
Cervera I (2000) Recursos de internet en alcoholismo. En Cuevas J, Sanchís M: Tratado de alcohología.
[48]
Tirapu J (2004) Cerebro y adicción: una guía comprensiva. Pamplona: Gobierno de Navarra, Departamento de Salud.
[49]
Koob GF (2006) Neurobiology of addiction. Ámsterdam,. Elsevier
[50]
Lizasoain I, Lorenzo P, Ladero JM, Leza JC (2003) Drogodependencias. Farmacología. Patología. Psicología. Legislación. Madrid: Editorial Panamericana (2ª edición).
[51]
Sociedad Española de Toxicomanías (2006). Tratado SET de trastornos adictivos. Madrid: Ed. Panamericana.
[52]
Kaplan & Sadock - Sadock BJ, Alcott V (2004) Sinopsis de psiquiatría. Ciencias de la conducta/Psiquiatría clínica (9ª edición). Ed. Waverly Hispánica,.
[53]
Fernández Miranda JJ, Gutiérrez Cienfuegos E, Marina Glez., P (Editores)(2002). Actuaciones clínicas en trastornos adictivos. Madrid, Ed. Aula Médica.
[54]
McIntyre JS, Pincus HA, Zarin DA: American Psychiatric Association APA. Guías clínicas para el tratamiento de los trastornos psiquiátricos. Ars Médica XXI, compendio 2008.
[55]
Adamson SJ, Todd FC, Sellman JD, et al.(2006) Co-existing psychiatric disorders in a New Zealand outpatients alcohol and other drug clinical population. Aust NZ J Psychiatry;40:164-170.
[56]
Badiani A, Belin D, Epstein D, Calu D, Shaham Y (2011) Opiate versus psychostimulant addiction: the differences do matter. Nature Reviews. Neuroscience., 12: 685-700.
[57]
Blanco C, Analucia A, Alegria BS et al (2012) Differences among major depressive disorder with and without Co-ocurring Substance Use Disorders and Substance-Induced Depressive disorder: results from the NESARC. J Clin Psychiatry; 73: 865-873.
[58]
Casas M. (2000) Trastornos duales. En: Vallejo Ruiloba J, Gastó Ferrer C (eds). Trastornos afectivos: ansiedad y depresión (2ª ed). Barcelona, Masson: 890-899.
[59]
Feltenstein MW, See RE (2008) The neurocircuitry of addiction: an overview. Br J Pharmacol 2008;154:261-274.
[60]
Frisher M, Crome I, Macleod J, et al. (2005) Substance misuse and psychiatric illness: prospective observational study using the general practice research database. J Epidemiol Community Health; 59: 847-850.
[61]
Hassin D, Samet S, Nunes E et al (2006) Diagnosis of comorbid psychiatric disorders in substance users assesses with the Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV. Am J Psychiatry; 163: 689-696.
[62]
Hasin D, Fenton MC, Skodol A, et al. (2011) Personality disorders and the 3-year course of alcohol, drug, and nicotine use disorders. Arch Gen Psychiatry; 68:1158-1167.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186